The National Medical Products Administration approves the marketing of Rosy Erythropoietin Alpha Injection-瞭望新时代网-瞭望时代，放眼世界

The National Medical Products Administration approves the marketing of Rosy Erythropoietin Alpha Injection

2026-03-20

According to the website of the National Medical Products Administration, recently, the National Medical Products Administration approved the application of Guangdong Sansheng Pharmaceutical Co., Ltd. for the launch of Roche erythropoietin alpha injection (trade name: New Bio Australia), which is used to treat anemia caused by chronic kidney disease and is currently undergoing erythropoietin treatment for hemodialysis patients. The launch of this variety provides new treatment options for relevant patients. (New Society)

Edit：WENWEN Responsible editor：LINXUAN

Source：people.com

Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com

Return to home page Return to list